...
sls-img

Sellas Life Sciences Group Inc, Common Stock

SLS

NAQ

$0.904

+$0.02

(2.27%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$62.06M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
926.88K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.40
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.5 L
$1.72 H
$0.904

About Sellas Life Sciences Group Inc, Common Stock

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSLSSectorS&P500
1-Week Return-15.22%-3.39%0.2%
1-Month Return-31.65%-1.92%2.72%
3-Month Return-30.02%-10.54%7.31%
6-Month Return-29.46%-4.47%10.44%
1-Year Return-21.28%4.06%27.53%
3-Year Return-86.2%0.94%30.88%
5-Year Return-76.98%36.67%89.21%
10-Year Return-100%102.87%199.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-1.90K7.60M1.00M-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.03,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":13.16,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue--200.00K100.00K-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":50,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit-1.90K7.40M900.00K-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.03,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":12.16,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin-100.00%97.37%90.00%-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.37,"profit":true},{"date":"2022-12-31","value":90,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses17.21M(18.88M)32.69M42.85M37.87M[{"date":"2019-12-31","value":40.16,"profit":true},{"date":"2020-12-31","value":-44.07,"profit":false},{"date":"2021-12-31","value":76.3,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":88.38,"profit":true}]
Operating Income(20.04M)(16.98M)(25.29M)(41.95M)(37.87M)[{"date":"2019-12-31","value":-2004100000,"profit":false},{"date":"2020-12-31","value":-1698200000,"profit":false},{"date":"2021-12-31","value":-2529400000,"profit":false},{"date":"2022-12-31","value":-4195000000,"profit":false},{"date":"2023-12-31","value":-3786900000,"profit":false}]
Total Non-Operating Income/Expense786.00K16.99M4.36M966.00K1.17M[{"date":"2019-12-31","value":4.63,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":25.68,"profit":true},{"date":"2022-12-31","value":5.69,"profit":true},{"date":"2023-12-31","value":6.89,"profit":true}]
Pre-Tax Income(19.37M)(16.77M)(20.94M)(41.30M)(37.34M)[{"date":"2019-12-31","value":-1937300000,"profit":false},{"date":"2020-12-31","value":-1677400000,"profit":false},{"date":"2021-12-31","value":-2093600000,"profit":false},{"date":"2022-12-31","value":-4130100000,"profit":false},{"date":"2023-12-31","value":-3734000000,"profit":false}]
Income Taxes(81.00K)(17.00K)(237.00K)(649.00K)(37.87M)[{"date":"2019-12-31","value":-8100000,"profit":false},{"date":"2020-12-31","value":-1700000,"profit":false},{"date":"2021-12-31","value":-23700000,"profit":false},{"date":"2022-12-31","value":-64900000,"profit":false},{"date":"2023-12-31","value":-3786900000,"profit":false}]
Income After Taxes(19.29M)(16.76M)(20.70M)(40.65M)529.00K[{"date":"2019-12-31","value":-3646.88,"profit":false},{"date":"2020-12-31","value":-3167.67,"profit":false},{"date":"2021-12-31","value":-3912.85,"profit":false},{"date":"2022-12-31","value":-7684.69,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income From Continuous Operations(19.29M)(16.76M)(20.70M)(41.30M)(38.33M)[{"date":"2019-12-31","value":-1929200000,"profit":false},{"date":"2020-12-31","value":-1675700000,"profit":false},{"date":"2021-12-31","value":-2069900000,"profit":false},{"date":"2022-12-31","value":-4130100000,"profit":false},{"date":"2023-12-31","value":-3832500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(19.29M)(16.76M)(20.70M)(40.65M)(37.34M)[{"date":"2019-12-31","value":-1929200000,"profit":false},{"date":"2020-12-31","value":-1675700000,"profit":false},{"date":"2021-12-31","value":-2069900000,"profit":false},{"date":"2022-12-31","value":-4065200000,"profit":false},{"date":"2023-12-31","value":-3734000000,"profit":false}]
EPS (Diluted)(21.72)(2.13)(1.33)(2.23)(1.36)[{"date":"2019-12-31","value":-2172,"profit":false},{"date":"2020-12-31","value":-213,"profit":false},{"date":"2021-12-31","value":-133,"profit":false},{"date":"2022-12-31","value":-223,"profit":false},{"date":"2023-12-31","value":-136,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SLS
Cash Ratio 1.99
Current Ratio 2.26

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SLS
ROA (LTM) -129.15%
ROE (LTM) -888.06%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SLS
Debt Ratio Lower is generally better. Negative is bad. 0.40
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.60

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SLS
Trailing PE NM
Forward PE NM
P/S (TTM) 26.90
P/B 4.07
Price/FCF NM
EV/R 20.84
EV/Ebitda NM

FAQs

What is Sellas Life Sciences Group Inc share price today?

Sellas Life Sciences Group Inc (SLS) share price today is $0.904

Can Indians buy Sellas Life Sciences Group Inc shares?

Yes, Indians can buy shares of Sellas Life Sciences Group Inc (SLS) on Vested. To buy Sellas Life Sciences Group Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SLS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Sellas Life Sciences Group Inc be purchased?

Yes, you can purchase fractional shares of Sellas Life Sciences Group Inc (SLS) via the Vested app. You can start investing in Sellas Life Sciences Group Inc (SLS) with a minimum investment of $1.

How to invest in Sellas Life Sciences Group Inc shares from India?

You can invest in shares of Sellas Life Sciences Group Inc (SLS) via Vested in three simple steps:

  • Click on Sign Up or Invest in SLS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Sellas Life Sciences Group Inc shares
What is Sellas Life Sciences Group Inc 52-week high and low stock price?

The 52-week high price of Sellas Life Sciences Group Inc (SLS) is $1.72. The 52-week low price of Sellas Life Sciences Group Inc (SLS) is $0.5.

What is Sellas Life Sciences Group Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Sellas Life Sciences Group Inc (SLS) is

What is Sellas Life Sciences Group Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Sellas Life Sciences Group Inc (SLS) is 4.07

What is Sellas Life Sciences Group Inc dividend yield?

The dividend yield of Sellas Life Sciences Group Inc (SLS) is 0.00%

What is the Market Cap of Sellas Life Sciences Group Inc?

The market capitalization of Sellas Life Sciences Group Inc (SLS) is $62.06M

What is Sellas Life Sciences Group Inc’s stock symbol?

The stock symbol (or ticker) of Sellas Life Sciences Group Inc is SLS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top